April 2024
Discussing AxSpA: Long-term etanercept response and real-world effectiveness of tofacitinib and adalimumab
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-world clinical context.
IMID Author Interview: Professor Frank Verhoeven, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Frank Verhoeven, an Assistant Professor in Rheumatology at the CHU Besancon in France, as they discuss his recent paper ‘Effects of disease‑modifying anti‑rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: A systematic review and meta‑analysis.’
Discussing RA: April 2024
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers related to the long-term safety of JAK inhibitors compared to TNF inhibitors. In our first paper, Christina Charles-Schoeman and colleagues assessed the risk of venous thromboembolism in patients with RA initiating tofacitinib or TNFi. Our second paper is from Roy Fleischmann and colleagues compare the long-term efficacy and safety data of upadacitinib switched from adalimumab and in adalimumab switched from upadacitinib. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Author Interview: Professor Maria Antonietta D’Agostino, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Maria Antonietta D’Agostino, the Head of the Rheumatology Department at the Catholic University of the Sacred Heart in Rome, as they discuss her recent paper 'Effects of Secukinumab on Synovitis and Enthesitis in Patients with Psoriatic Arthritis: 52-week Clinical and Ultrasound Results from the Randomised, Double-blind ULTIMATE Trial with Open Label Extension'.
Author Interview: Professor Dennis McGonagle, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Dennis McGonagle, a Clinical Professor at the University of Leeds School of Medicine, as they discuss his recent paper ‘Association of the Clinical Components in the Distal Interphalangeal Joint Synovio-entheseal Complex and Subsequent Response to Ixekizumab or Adalimumab in Psoriatic Arthritis.’
Discussing AxSpA: Secukinumab retention over time & sacroiliac joint improvements between DMARDs
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs.